# Tau PNU MEDICAL Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tau-pnu-medical-co

- Industry: Medical Devices & Equipment
- Headquarters: Busan, South Korea
- Website: www.tau-pnu.co.kr
- Total disclosed funding: $25M
- Latest round: Series B (Sep 30, 2020)
- Investors on record: 3

## About

Tau-Medical Inc., doing business as Tau Medical, specializes in innovative medical devices designed to treat tricuspid regurgitation, offering advanced solutions that enhance patient care without invasive surgical methods. Founded in 2014 and headquartered in Busan, South Korea, Tau Medical operates in the medical technology sector focusing on devices for cardiac treatment. In September 2026, Tau Medical raised KRW 50 billion in pre-IPO funding from new investors WONIK Investment Partners, Timefolio Asset Management, Vision Equity Partners and Loftyrock Investment. Returning investor Smilegate Investment also participated in the round.
Tau Medical specializes in innovative medical devices aimed at addressing tricuspid regurgitation (TR) through their proprietary Pivot-TR platform. The core offerings include two distinct solutions: Pivot Extend®, a permanent implant designed for long-term valve support, and Pivot Bridge®, a temporary device that stabilizes frail or high-risk patients while facilitating their transition to future therapies. Both products utilize a minimally invasive transfemoral approach, negating the need for open-heart surgery and utilizing atraumatic anchoring that avoids tissue fixation. The target user base encompasses healthcare providers, particularly cardiologists and surgeons, who are tasked with treating patients suffering from TR, including those previously deemed too high-risk for such interventions. The Pivot-TR solutions are designed for use in various global markets, including North America and Europe, where the demand for advanced cardiac therapies continues to grow.Tau Medical generates revenue primarily through the sale of its Pivot-TR products, engaging directly with healthcare institutions and medical practitioners who perform cardiac procedures. The transaction structure is based on a direct-to-consumer model in the B2B space, with hospitals and clinics purchasing the devices as needed for their patients. Given the specialized nature of the products, the revenue cycle includes one-time purchases of the implants, with potential for ongoing partnerships for training and support services related to the use of the devices. While specific pricing structures for the products are not disclosed, it is anticipated that pricing reflects the advanced technology and clinical benefits provided by these innovative solutions.
The company will use the funding to support final-stage regulatory approvals, commercialize its catheter-based heart valve treatment devices, strengthen its position in global markets, and advance its IPO preparations.

## Funding rounds

- Series B, Sep 30, 2020, $21M — BNK Venture Capital
- Series A, Sep 15, 2017, $4.4M — Smilegate Investment, K Bridge Ventures

## Investors

- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A
- K Bridge Ventures — Series A
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series B